Assessing the safety of sitagliptin in older participants in the trial evaluating cardiovascular outcomes with sitagliptin (TECOS)

Diabetes Care

Volumn 40, Issue 4, 2017, Pages 494-501

  Bethel, M Angelyn ^a   Engel, Samuel S ^b   Green, Jennifer B ^c   Huang, Zhen ^c   Josse, Robert G ^d   Kaufman, Keith D ^b   Standl, Eberhard ^e   Suryawanshi, Shailaja ^b   Van De Werf, Frans ^f   McGuire, Darren K ^g   Peterson, Eric D ^c   Holman, Rury R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e Helmholtz Centre for Environmental Health   (Germany)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SITAGLIPTIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ACUTE PANCREATITIS; ADULT; AGED; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; INFORMED CONSENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON MELANOMA SKIN CANCER; PANCREAS CANCER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; BODY MASS; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; FOLLOW UP; HYPOGLYCEMIA; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTOR; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; SITAGLIPTIN PHOSPHATE; STROKE; TREATMENT OUTCOME;

EID: 85019638259     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-1135     Document Type: Conference Paper

References (19)

1. Murray CJ, Barber RM, Foreman KJ, et al.; GBD 2013 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990- 2013: quantifying the epidemiological transition. Lancet 2015;386:2145-2191
2. Cheng YJ, Imperatore G, Geiss LS, et al. Secular changes in the age-specific prevalence of diabetes among U.S. adults: 1988-2010. Diabetes Care 2013;36:2690-2696
3. Gregg EW, Cheng YJ, Saydah S, et al. Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey. Diabetes Care 2012;35:1252-1257
4. Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH, Karter AJ. Rates of complications and mortality in older patients with diabetes mellitus: the Diabetes and Aging Study. JAMA Intern Med 2014;174:251-258
5. Lakey WC, Barnard K, Batch BC, Chiswell K, Tasneem A, Green JB. Are current clinical trials in diabetes addressing important issues in diabetes care? Diabetologia 2013;56:1226-1235
6. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-242
7. Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J 2013;166:983-989.e7
8. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus [Internet], 2012. Available from http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/06/WC500129256.pdf. Accessed 20 April 2016
9. WhiteWB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335
10. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
11. Leiter LA, Teoh H, Braunwald E, et al.; SAVORTIMI 53 Steering Committee and Investigators. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care 2015;38:1145-1153
12. Townsend N, Williams J, Bhatnagar P, Wickramasinghe K, Rayner M. Cardiovascular Disease Statistics, 2014. London, British Heart Foundation, 2014
13. Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly:morbidity, mortality, and costs. Clin GeriatrMed 2009;25:563-577, vii
14. Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, et al.; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statisticsd2016 update: a report from the American Heart Association. Circulation 2016;133:447-454
15. Heidenreich PA, Trogdon JG, Khavjou OA, et al.; American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123:933-944
16. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in theUnited States, 2014. Atlanta, GA, U.S. Department of Health and Human Services, 2014
17. American Diabetes Association. Summary of revisions. In Standards of Medical Care inDiabetesd 2016. Diabetes Care 2016;39(Suppl. 1):S4-S5
18. International Diabetes Federation. Managing Older People With Type 2 Diabetes: Global Guideline. Brussels, Belgium, International Diabetes Federation, 2013
19. Moreno G, MangioneCM, Kimbro L, Vaisberg E; American Geriatrics Society Expert Panel on Care of Older Adults with Diabetes Mellitus. Guidelines abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adultswith DiabetesMellitus: 2013 update. J Am Geriatr Soc 2013;61:2020-2026